Publications
363 publications
- Date
- Relevance
-
Package advice acalabrutinib (Calquence®) for the treatment of chronic lymphatic leukaemia
The National Health Care Institute has completed its assessment whether acalabrutinib (Calquence®) can be included in the insured ...
-
GVS advice on volanesorsen (Waylivra)
The National Health Care Institute advises the Minister to include volanesorsen on List 1B of the GVS. Volanesorsen (Waylivra®) ...
-
GVS advice Tezacaftor/ivacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) extension of further conditions
The National Health Care Institute completed its assessment whether the further conditions of tezacaftor/ivacaftor (Symkevi®) and ...
-
Package advice ravulizumab (Ultomiris®) for the treatment of PNH and aHUS
The National Health Care Institute has completed its assessment whether ravulizumab (Ultomiris®) can be included in the insured ...
-
GVS advice tirbanibulin (Klisyri®) for the treatment of adults with actinic keratosis
The National Health Care Institute recommends the Minister to include tirbanibulin on List 1A in cluster 0D06BBADC V of the GVS. ...
-
GVS advice fostemsavir (Rukobia®) for the treatment of adults with multidrug resistant HIV-1 infection
The National Health Care Institute recommends the Minister to include fostemsavir (Rukobia®) in the GVS on List 1B and List 2 of ...
-
Package advice for the lock procedure drug osimertinib (Tagrisso®)
The National Health Care Institute has completed its assessment whether osimertinib (Tagrisso®) can be included in the insured ...
-
Package advice venetoclax (Venclyxto®)
The National Health Care Institute has completed its assessment whether venetoclax (Venclyxto®) can be included in the insured ...
-
GVS advice on levodopa/carbidopa/entacapon intestinal gel (Lecigon®) for the treatment of Parkinson's disease
The National Health Care Institute advises the Minister to include Lecigon® intestinal gel in the GVS only if a price adjustment ...
-
GVS assessment ponesimod (Ponvory®) for the treatment of relapsing forms of multiple sclerosis (RMS)
National Health Care Institute has completed its assessment whether ponesimod (Ponvory®) can be included in the ...